Abstract Objectives/Hypothesis: To design a grading scale and audiologic protocols to better
reflect clinical impact than the currently widely used classifications. Study Design …

Background: Cisplatin is effective in the treatment of several cancers but is a known ototoxin
resulting in shifts to hearing sensitivity in up to 50–60% of patients. Cisplatin-induced …

The success of contemporary treatment in curing over 70% of children with cancer, including
leukaemia [1], is tempered by the development of late adverse effects of treatment in many …

The aim of this study was to investigate long-term development of hearing in subjects who
had received platinum-based chemotherapy in childhood or adolescence. Another aim was …

Cisplatin has dramatically improved the survival rate of cancer patients, but it has also
increased the prevalence of hearing and neurological deficits in this population. Cisplatin …

Background Platinum‐based therapy, including cisplatin, carboplatin or oxaliplatin, or a
combination of these, is used to treat a variety of paediatric malignancies. Unfortunately, one …

The impact of cancer interventions has been conducted in several research due to the
significant burden of this non-communicable disease. The interventions that played an …

Purpose A growing number of patients with testicular cancer (TC) become long-term
survivors. As a consequence, quality-of-life (QOL) issues become increasingly important …

Purpose: Cisplatin, a commonly used chemotherapeutic, results in tinnitus, the phantom
perception of sound. Our purpose was to identify the clinical and genetic determinants of …

Purpose: Cisplatin is a first-line chemotherapeutic for many cancers, but causes
neurotoxicity including hearing loss, tinnitus, and peripheral sensory neuropathy. However …